US pharmaceutical company Jansssen holds the rights for Darzalex, which was developed by Danish biotech firm Genmab and has had significantly better sales than expected in this year's first quarter.
While analysts had forecast that Darzalex would sell for around USD 1.25bn, Janssen has fetched USD 1.37bn from this cancer drug, which is around 46 percent more than the same quarter in 2020.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.